Insight

Unmet needs, uncommon commitment: The shift toward investment in rare diseases

Unmet needs, uncommon commitment: The shift toward investment in rare diseases

Join biotech leaders, emerging innovators, investors and patient advocacy group reps for a candid, interactive and enlightening discussion about rare disease drug discovery and development.

ClearView: Should you partner or go it alone?

ClearView: Should you partner or go it alone?


Aug 17, 2017

Partnering isn’t an all-or-nothing, one-size-fits-all commercialization plan. There are a multitude of options and strategies, including the option of choosing not to partner. To decide...

Merck values innovation…in deals and ideas

Merck values innovation…in deals and ideas


Aug 17, 2017

The key to getting Merck’s attention is to have a highly differentiated product that makes a substantial difference in patients’ lives. Having clinical data helps,...

partnering360®: leverage and cultivate your dealmaker network

partnering360 is the network for dealmakers in the life science industry. This global community of more than 39,000 is constantly growing, and the partnering opportunities continually updating.